BIIB Q4 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B+2.9% YoY

Gross Profit

$1.9B76.2% margin

Operating Income

$509M20.7% margin

Net Income

$267M10.9% margin

EPS (Diluted)

$1.83

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

$761M

Free Cash Flow

$695M

Stock-Based Comp.

$75M

Balance Sheet

Total Assets

$28.0B

Total Liabilities

$11.3B

Stockholders' Equity

$16.7B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.4B	+2.9%
Gross Profit	$1.9B	$1.8B	+5.8%
Operating Income	$509M	$512M	-0.7%
Net Income	$267M	$250M	+6.8%

Revenue Segments

MS Product Revenues

$1.1B42%

SPINRAZA

$421M17%

TYSABRI product

$415M16%

Fumarate

$404M16%

Interferon

$236M9%

Geographic Segments

Non-US

$1.0B55%

UNITED STATES

$832M45%